Suven Life Sciences Ltd presents Masupirdine and Tenaclidine data at CTAD-2026, with Masupirdine Phase 3 results expected in Q2 2027
- Masupirdine presentation covers baseline demographic and clinical characteristics; global Phase 3 enrollment is complete.
- Tenaclidine presentation covers Phase 1 safety, tolerability and pharmacokinetics.
- Suven said Tenaclidine’s clinical findings support advancing to patient studies.
